HK1020017A1 - Therapeutic treatment for vegf related occular diseases. - Google Patents

Therapeutic treatment for vegf related occular diseases.

Info

Publication number
HK1020017A1
HK1020017A1 HK99105357A HK99105357A HK1020017A1 HK 1020017 A1 HK1020017 A1 HK 1020017A1 HK 99105357 A HK99105357 A HK 99105357A HK 99105357 A HK99105357 A HK 99105357A HK 1020017 A1 HK1020017 A1 HK 1020017A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic treatment
vegf related
occular diseases
occular
diseases
Prior art date
Application number
HK99105357A
Other languages
English (en)
Inventor
Lloyd P Aiello
Michael R Jirousek
George L King
Louis Vignati
Douglas Kirk Ways
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1020017A1 publication Critical patent/HK1020017A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK99105357A 1996-05-01 1999-11-19 Therapeutic treatment for vegf related occular diseases. HK1020017A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US08/841,739 US6114320A (en) 1996-05-01 1997-04-30 Therapeutic treatment for VEGF related ocular diseases
PCT/US1997/007800 WO1997040831A1 (en) 1996-05-01 1997-05-01 Therapeutic treatment for vegf related occular diseases

Publications (1)

Publication Number Publication Date
HK1020017A1 true HK1020017A1 (en) 2000-03-10

Family

ID=26688915

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99105357A HK1020017A1 (en) 1996-05-01 1999-11-19 Therapeutic treatment for vegf related occular diseases.

Country Status (22)

Country Link
US (1) US6114320A (xx)
EP (1) EP0918519B1 (xx)
JP (1) JP4122060B2 (xx)
KR (1) KR100364487B1 (xx)
CN (1) CN1158073C (xx)
AT (1) ATE270548T1 (xx)
AU (1) AU724923B2 (xx)
BR (1) BR9710705A (xx)
CA (1) CA2253613C (xx)
CZ (1) CZ296711B6 (xx)
DE (1) DE69729798T2 (xx)
EA (1) EA001752B1 (xx)
ES (1) ES2224249T3 (xx)
HK (1) HK1020017A1 (xx)
HU (1) HU226378B1 (xx)
IL (1) IL126836A (xx)
NO (1) NO322209B1 (xx)
NZ (2) NZ538109A (xx)
PL (1) PL189020B1 (xx)
PT (1) PT918519E (xx)
UA (1) UA54427C2 (xx)
WO (1) WO1997040831A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
EP1105136B1 (en) * 1998-08-13 2007-08-29 Novartis AG Method for treating ocular neovascular diseases
US6214819B1 (en) 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
ES2211197T3 (es) * 1998-11-23 2004-07-01 Novartis Ag Uso de derivados de estaurosporina para tratar enfermedades neovasculares oculares.
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
IL151045A0 (en) 2000-02-07 2003-04-10 Abbott Gmbh & Co Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
EP2319493A3 (en) * 2002-07-23 2011-07-27 Novartis AG Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
US20070059381A1 (en) * 2003-06-20 2007-03-15 Barker Ronnie C Treatment of amd with combination of ingredients
JP2007529434A (ja) * 2004-03-17 2007-10-25 ラース マイケル ラーセン, 視覚サイクルの阻害による網膜症の予防
BRPI0509576A (pt) 2004-04-02 2007-05-29 Osi Pharm Inc composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
AU2007286817A1 (en) * 2006-08-23 2008-02-28 Novartis Ag Use of PKC inhibitors in particular indolylmaleimide derivatives in ocular diseases
EP2089016A4 (en) * 2006-10-03 2014-10-08 Univ Pennsylvania METHOD FOR TREATING MACULAR AGENCY
US10360673B2 (en) 2015-03-26 2019-07-23 Eyekor, Llc Image analysis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
IL111851A (en) * 1993-12-07 1998-09-24 Lilly Co Eli Improved synthesis of bisindolylsimilides and process for its preparation
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CN1050844C (zh) * 1993-12-07 2000-03-29 伊莱利利公司 蛋白激酶c抑制剂
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
NO985067D0 (no) 1998-10-30
PT918519E (pt) 2004-10-29
NZ538109A (en) 2006-10-27
NO322209B1 (no) 2006-08-28
EP0918519B1 (en) 2004-07-07
AU724923B2 (en) 2000-10-05
EP0918519A1 (en) 1999-06-02
JP2000514402A (ja) 2000-10-31
CN1158073C (zh) 2004-07-21
DE69729798D1 (de) 2004-08-12
KR100364487B1 (ko) 2003-01-25
AU2936197A (en) 1997-11-19
ES2224249T3 (es) 2005-03-01
PL330463A1 (en) 1999-05-24
NO985067L (no) 1998-12-22
BR9710705A (pt) 1999-08-17
HU226378B1 (en) 2008-10-28
EA001752B1 (ru) 2001-08-27
ATE270548T1 (de) 2004-07-15
CA2253613C (en) 2007-11-27
EA199800970A1 (ru) 1999-06-24
CN1222850A (zh) 1999-07-14
HUP9902805A2 (hu) 2000-02-28
DE69729798T2 (de) 2005-08-25
IL126836A (en) 2004-05-12
JP4122060B2 (ja) 2008-07-23
NZ332833A (en) 2000-07-28
CA2253613A1 (en) 1997-11-06
KR20000065172A (ko) 2000-11-06
UA54427C2 (uk) 2003-03-17
EP0918519A4 (en) 1999-08-11
CZ296711B6 (cs) 2006-05-17
IL126836A0 (en) 1999-09-22
PL189020B1 (pl) 2005-06-30
HUP9902805A3 (en) 2000-04-28
CZ349998A3 (cs) 1999-11-17
WO1997040831A1 (en) 1997-11-06
US6114320A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
HK1020017A1 (en) Therapeutic treatment for vegf related occular diseases.
UA84665C2 (ru) Способ ингибирования опосредствованного ангиогенеза в ткани у пациента с неоваскулярным заболеванием роговицы
EA199800971A1 (ru) Способ лечения новообразований, вкючающий применение ингибиторов протеиназы с
ATE315933T1 (de) Therapeutische behandlung von kardiovaskularen krankheiten
PT829262E (pt) Utilizacao de inibidores de pkc para o fabrico de um medicamento para o tratamento de disfuncoes sexuais.
EP0940141A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection
EP0940143A3 (en) Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma
NO990949L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS
EP0940142A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
NO990947L (no) Anvendelse av inhibitorer for PKC til fremstilling av et medikament for behandling av sentralnervesystemsykdommer forbundet med HIV-infeksjon
NO990948L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner
US5721216A (en) Treatment of diseases caused by parasitic protozoa and fungal diseases by administration of 5-deoxy-5-(substituted) ethylthioribose compounds
HUP9903911A2 (hu) PKC inhibitorok alkalmazása a központi idegrendszer HIV-fertőzéssel kapcsolatos megbetegedéseinek kezelésére szolgáló gyógyászati készítmények előállítására
SI0918519T1 (en) Therapeutic treatment for vegf related occular diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120501